ARSI (Arylsulfatase Family Member I)

Downstream analysis validated the reliability of the method, confirming its effectiveness in cell annotation, functional enrichment, and mechanistic studies. AugGCL generates clearer spatial domains and significantly advances the application of spatial transcriptomics in tissue structure and disease research.

P=N/A, N=70, Recruiting, Stanford University | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Jan 2026 | Trial primary completion date: Dec 2026 --> Dec 2027

The package offers a command-line-based interface and data visualisation routines. The package is available at https://github.com/uio-bmi/StarSignDNA and can be installed via PyPI.

The performance of our method has been assessed through numerical simulations and implantation experiments. Results have demonstrated superior performance in both source localization and morphological restoration, thereby highlighting its potential for advancing CB-XLCT toward preclinical and clinical applications.

Img2ST-Net offers a principled solution for efficient and accurate ST inference at scale. Our contributions lay the groundwork for next-generation ST modeling that is robust and resolution-aware.

Across bulk, single‑cell, and spatial layers, COL22A1 integrates molecular, cellular, and microenvironmental hallmarks of glioma aggressiveness. Its tumour‑centric expression, peri‑necrotic localisation, and independent prognostic value support COL22A1 as a robust biomarker and a tractable candidate for imaging or therapeutic strategies in treatment‑refractory disease.

In this analysis of patients with early PSMA PET follow-up after ARSi initiation, we observed a PSMA-upregulation by WB-PET imaging in 25% of the patients. Further studies are needed to better understand the potential synergistic and / or additive effects of AR- and PSMA-targeted approaches.

In cisplatin-treated TNBC patient-derived xenografts, we identify therapy-induced mutagenesis and inactivation of APOBEC3 activity...Additionally, we detect a clone-specific increase in SBS17 activity, in a clone previously linked to recurrence. Our findings establish ultra-low-coverage scWGS as a powerful approach for studying active mutational processes that may influence ongoing clonal evolution and therapeutic resistance.

Combined therapy reduced the risk of rPFS, with the response higher in PTEN-loss subgroup, with a modest but not significant increase in OS. Our AE estimates showed consistency with other studies. AEs of any grade were common with the majority experiencing at least 1 AE. (PROSPERO Registration Number: CRD420202352583).

Patients with rapid PSADT are at increased risk of early disease progression, suggesting that immediate treatment may be warranted. In addition, initiating therapy at a PSA level <5.4 ng/ml may be associated with improved patient outcomes in patients with low PSADT.

Inhibition of the Cdc2-like kinase (CLK) family by the small molecules cirtuvivint or lorecivivint results in the decreased expression of ARV7. Both inhibitors show potent anti-proliferative effects in enzalutamide-treated or -naive PC models. Thus, targeting aberrant alternative splicing at the 3'UTR of ARV7 by disturbing the CLK2/SRSF9 axis might be a valuable therapeutic approach in late stage, ARSI-resistant PC.

For UC, insights emerged from adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and from the efficacy of the EV-302 study of enfortumab vedotin +pembrolizumab in the metastatic setting...In metastatic castration-resistant PC, highlights included a novel combo (cabozantinib+atezolizumab) for poor prognosis patients; confirmed benefits of ARSI+PARPi in BRCA-mutated patients; and safety considerations for ARSI treatments. The symposium continued its role as an indispensable platform for shaping specialized oncological care.